P-gp inhibition potential in cell-based models: Which "calculation" method is the most accurate?

AAPS Journal

Volumn 10, Issue 4, 2008, Pages 577-586

  Balimane, Praveen V ^a   Marino, Anthony ^a   Chong, Saeho ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Drug drug interactions; Effluxratio; In vitro models; P gp inhibition; Permeability

Indexed keywords

DIGOXIN; ELACRIDAR; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; INDINAVIR; SAQUINAVIR; VERAPAMIL; VERLUKAST; PROPIONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; QUINOLINE DERIVATIVE;

ANALYTIC METHOD; ARTICLE; CELL ASSAY; CONTROLLED STUDY; DRUG RESEARCH; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; PERMEABILITY; PROTEIN DETERMINATION; RELIABILITY; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; KINETICS; METABOLISM; METHODOLOGY; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; DIGOXIN; DRUG EVALUATION, PRECLINICAL; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; KINETICS; P-GLYCOPROTEIN; PROPIONATES; QUINOLINES; SAQUINAVIR; VERAPAMIL;

EID: 65549102615     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-008-9068-x     Document Type: Article

References (26)

1. E. Leahey, et al. Interaction between quinidine and digoxin. JAMA. 240: 533-534 (1978).
2. J. Lin. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv. Drug Deliv. Rev. 55:53-81 (2003).
3. J. Lin, and M. Yamazaki. Role of P-glycoprotein in pharmacokinetics. Clin Pharmacokinet. 42:59-98 (2003).
4. C. Matheny, M. Lamb, K. Brouwer, and G. Pollak. Pharmacokinetic and pharmacodynamic implications of P-gp modulation. Pharmacotherapy. 21: 778-796 (2001).
5. J. Polli, et al. Role of P-gp on CNS disposition of amprenavir, an HIV protease inhibitor. Pharm. Res. 16:1206-1212 (1999).
6. J. W. Polli, et al. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. J. Pharm. Sci. 92:2082-2089 (2003).
7. A. Sparreboom, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-gp in the intestine. Proc. Natl. Acad. Sci. 94:2031-2035 (1997).
8. T. Watanabe, et al. Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver: Possible roles of P-gp in biliary excretion of vincristine. J. Hepatol. 16:77-88 (1992).
9. FDA Draft Guidance. Drug interaction studies - Study design, data analysis, and implications for dosing and labeling. 2006.
10. P. V. Balimane, Y. H. Han, and S. Chong. Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J. 8:E1-13 (2006).
11. L. Cutler, C. Howes, N. J. Deeks, T. L. Buck, and P. Jeffrey. Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier. J. Pharm. Sci. 95:1944-1953 (2006).
12. B. Feng, et al. In vitro p-glycoprotein assays to predict the in vivo interactions of p-glycoprotein with drugs in the central nervous system. Drug. Metab. Dispos. 36:268-275 (2008).
13. I. Hidalgo. Assessing the absorption of new pharmaceuticals. Current Topics in Medicinal Chemistry. 1:385-401 (2001).
14. J. P. Keogh, and J. R. Kunta. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur. J. Pharm. Sci. 27:543-554 (2006).
15. E. Kerns, et al. Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. J. Pharm. Sci. 93:1440-1453 (2004).
16. J. Polli, et al. Rational use of in vitro P-gp assays in drug discovery. J. Pharmacol. Exp. Ther. 299:620-628 (2001).
17. J. Rautio, et al. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: A recommendation for probe substrates. Drug Metab. Dispos. 34:786-792 (2006).
18. F. Tang, K. Horie, and R. Borchardt. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa. Pharm. Res. 19:765-772 (2002).
19. A.-L. Ungell. Caco-2 replace or refine. Drug Discov. Today. 1:423-430 (2004).
20. P. Hsiao, T. Bui, R. J. Ho, and J. D. Unadkat. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier. Drug. Metab. Dispos. 36:481-484 (2008).
21. R. Kim, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-gp. Pharm. Res. 16:408-414 (1999).
22. M. Perloff, E. Stromer, L. von Moltke, and D. Greenblatt. Rapid assessment of P-gp inhibition and induction in vitro. Pharm. Res. 20:1177-1183 (2003).
23. M. D. Troutman, and D. R. Thakker. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: Asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm. Res. 20:1200-1209 (2003).
24. R. Stephens, et al. Kinetic profiling of P-gp mediated drug efflux in rat and human intestinal epithelia. J. Pharmacol. Exp. Ther. 296:584-591 (2001).
25. P. V. Balimane, and S. Chong. Cell culture-based models for intestinal permeability: A critique. Drug Discov. Today. 10:335-343 (2005).
26. P. V. Balimane, K. Patel, A. Marino, and S. Chong. Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery. Eur. J. Pharm. Biopharm. 58:99-105 (2004).